



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

Microglial Activation and Inhibition: Implications for Neurodegeneration

Hannah Mary Gibbons

A thesis submitted in partial fulfilment of the requirements for the degree of Doctor of Philosophy, Faculty of Medicine and Health Science, The University of Auckland, 2004

Abstract

Accumulating evidence over the past 20 years has indicated that the brain has an endogenous immune system, mediated at the local level predominantly by microglial cells. The primary role of an inflammatory response is to protect the host against a foreign stimulus, remove damaged cells and to initiate repair and regeneration of damaged tissue. However, it has become increasingly evident that this inflammatory response, in addition to its role in host defence and repair, can exert detrimental effects in the central nervous system (CNS). Neuroinflammation, as this response is now commonly known, has been implicated in the pathogenesis of many neurodegenerative diseases. Microglia, the resident macrophage of the brain, play a central role in sustaining this inflammatory response through the release of pro-inflammatory and potentially cytotoxic mediators. Hypothermia is neuroprotective, and these properties are thought to be mediated, in part, by the suppression of microglial activation.

The BV-2 microglial cell line was used to investigate the mechanisms involved in the activation and inhibition of microglia. Lipopolysaccharide (LPS)-induced activation of BV-2 cells led to the up-regulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, the release of inflammatory mediators such as nitric oxide (NO), prostaglandin (PG)-E₂, interleukin (IL)-6 and tumour necrosis factor (TNF)- α , and a change to a phagocytic phenotype. This response was mediated by the initiation of signal transduction pathways that culminated in transcription and translation of the inflammatory genes. Hypothermia (33°C) caused complete suppression of iNOS and NO whilst displaying little or no effect on IL-6 and TNF- α respectively. In contrast, LPS-induced COX-2 expression and PGE₂ release was super-induced in response to hypothermia. A co-culture model of neuroinflammation was developed to investigate microglial-neuronal interactions. LPS/interferon (IFN)- γ activated BV-2 cells required direct contact with SK-N-SH neuroblastoma cells to elicit a cytotoxic phenotype. Hypothermia and the selective iNOS inhibitor *S*-methylisothiourea (*S*-MT) protected against this BV-2-induced SK-N-SH cell death, strongly implicating NO as the major candidate molecule in microglial-induced neuronal cell death.

Thus, microglial activation sustains the chronic inflammatory response in the CNS and in doing so contributes to further neuronal death. Inhibition of the detrimental facets of microglial activation may provide some protection against neurodegeneration.

Acknowledgments

This thesis would not be complete without an expression of thanks to all those people who made it possible. Firstly, I would like to thank my supervisor Professor Mike Dragunow for his support and direction throughout this research project. Mike, your cry of "results, results, results" and your endless enthusiasm for research has been inspirational. I would also like to thank my associate supervisors Professor Richard Faull and Dr Russell Snell for creating the wonderful learning environment that is the HRC Neuro group.

A special thank you to all the members of the Molecular Neuropharmacology Research Group. Thanks to Jeff Greenwood, Carol Gray and Chris Lind for imparting their extensive knowledge and wisdom. Thanks to the newer members of the lab, Jo Lim, Paul Battersby and Pritika Narayan for bringing a fresh outlook on life. A big thank you to Rachel Cameron and Andree Pearson - friends and co-PhD students, who have shared the highs and the lows with me, and made it a very enjoyable experience. I would also like to acknowledge the members of the wider HRC Group, who have given me support and fun weekends away over the past few years. Thank you also to Ingrid Piepereit and to the soccer girls - your fun loving ways and support without knowing the in's and out's of my thesis has been a constant source of strength, and to Bernadine Hill for proofreading and good friendship.

I am indebted to the Health Research Council of New Zealand for enabling me to work as an Associate Research Fellow whilst undertaking my PhD. The New Zealand Neurological Foundation, the Health Research Council of New Zealand, the Maurice and Phyllis Paykel Trust and the Department of Pharmacology have provided me with funding to enable me to attend international conferences.

Last, but by no means least, I would like to take this opportunity to thank my family and friends for their constant love and support. Mum, Dad, Vicky and Philip, I could never have done this without you. You have always supported me in anything that I have wanted to do, and for that I am eternally grateful. Simon, your love and understanding has given me the strength to fulfil my dreams. Thank you.

Table of Contents

Abstract.....	ii
Acknowledgments.....	iii
List of Figures.....	viii
List of Tables.....	xii
Abbreviations.....	xiii
1 General Introduction.....	1
1.1 CNS disorders with an inflammatory component.....	3
1.1.1 Alzheimer's disease.....	3
1.1.2 Parkinson's disease.....	6
1.1.3 Stroke.....	9
1.2 CNS cell types involved in neuroinflammation.....	10
1.2.1 Microglia.....	11
1.2.2 Astrocytes.....	13
1.2.3 Neurons.....	14
1.2.4 T-cells.....	15
1.2.5 Oligodendrocytes.....	15
1.3 Mediators of the inflammatory response.....	15
1.3.1 Nitric Oxide Synthase, Nitric Oxide and Peroxynitrite.....	16
1.3.1.1 Neuronal nitric oxide synthase.....	16
1.3.1.2 Endothelial nitric oxide synthase.....	17
1.3.1.3 Inducible nitric oxide synthase.....	18
1.3.1.4 Peroxynitrite.....	19
1.3.2 Cyclooxygenase and Prostaglandins.....	20
1.3.2.1 Cyclooxygenase-1.....	20
1.3.2.2 Cyclooxygenase-2.....	20
1.3.2.3 Prostaglandin E ₂	22
1.3.3 Cytokines.....	23
1.3.3.1 Interleukin-6.....	24
1.3.3.2 Tumour necrosis factor- α	25
1.3.4 Complement.....	27
1.3.5 Free radicals and oxidative stress.....	29
1.3.6 Additional mediators of neuroinflammation.....	30
1.4 Inhibitors of the inflammatory response.....	30
1.4.1 Hypothermia.....	31
1.4.2 Anti-inflammatory cytokines – Interleukin-10.....	33
1.4.3 Non-steroidal anti-inflammatory drugs.....	34

1.4.4	Anti-inflammatory prostaglandins - 15-deoxy- $\Delta^{12,14}$ -PGJ ₂	36
1.4.5	Immunisation.....	37
1.5	Aims.....	38
2	Materials and Methods.....	40
2.1	Cell culture.....	40
2.1.1	BV-2 Microglial cell line.....	40
2.1.2	P19 cell line.....	40
2.1.3	Neuro 2a cell line.....	41
2.1.4	SK-N-SH cell line.....	41
2.1.5	Co-cultures.....	42
2.1.6	Trans-well cultures.....	42
2.1.7	Conditioned medium.....	42
2.2	Activation of cell cultures.....	43
2.3	Phagocytosis assay.....	44
2.4	Proliferation assay.....	44
2.5	Cell viability assays.....	45
2.5.1	MTT assay.....	45
2.5.2	AlamarBlue assay.....	45
2.6	Nitric oxide assay.....	45
2.7	Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR).....	46
2.7.1	RNA extraction.....	46
2.7.2	cDNA synthesis.....	46
2.7.3	PCR amplification.....	46
2.8	Fixation of cells.....	48
2.9	Cresyl Violet staining.....	48
2.10	Immunocytochemistry (ICC).....	48
2.10.1	DAB ICC.....	48
2.10.2	Fluorescence ICC.....	49
2.11	Microscopy and photography.....	49
2.12	Cell counting.....	49
2.12.1	Manual.....	49
2.12.2	Discovery-1.....	49
2.13	Cell-based ELISA.....	50
2.14	Western Blot.....	50
2.14.1	Preparation of protein lysates.....	50
2.14.2	SDS-PAGE electrophoresis.....	51
2.14.3	Western blotting and antibody detection.....	51
2.14.4	Membrane stripping.....	51
2.15	ELISA.....	52

2.16	RIA.....	53
2.17	Statistical analysis	53
3	Characterisation of BV-2 cells as an <i>in vitro</i> model of microglia.....	54
3.1	Introduction.....	54
3.2	Results.....	55
3.2.1	Cell Morphology and proliferation.....	55
3.2.2	Inducible NOS protein expression and NO release	57
3.2.3	Time course of expression of iNOS and COX-2	57
3.2.4	Cytokine production	60
3.2.5	Phagocytosis	60
3.2.6	Suppression of LPS-induced activation of BV-2 cells with IL-10 and 15d-PGJ ₂	63
3.2.6.1	IL-10	63
3.2.6.2	15d-PGJ ₂	63
3.3	Discussion	67
4	Effect of hypothermia on microglial activation.....	76
4.1	Introduction.....	76
4.2	Results.....	77
4.2.1	Inhibition of LPS-induced iNOS expression and NO release by hypothermia.....	77
4.2.2	Effect of hypothermia on LPS-induced IL-6 and TNF- α release and translocation of NF- κ B	79
4.2.3	Suppression of BV-2 cell proliferation by hypothermia	82
4.2.4	Increased LPS-induced COX-2 expression by hypothermia	82
4.3	Discussion	85
5	Effect of hypothermia on LPS-induced signal transduction pathways.....	92
5.1	Introduction.....	92
5.2	Results.....	95
5.2.1	MEK-ERK1/2 pathway	95
5.2.2	JNK pathway	103
5.2.3	p38 MAPK pathway	112
5.2.4	NF- κ B pathway	118
5.2.5	Transcription factors.....	118
5.2.6	Apoptosis markers	121
5.2.7	Inflammatory mediators	121
5.3	Discussion	128
6	MAP kinase signalling pathways in activated microglia.....	137
6.1	Introduction.....	137
6.2	Results.....	139

6.2.1	U0126-mediated inhibition of the MEK-ERK pathway	139
6.2.2	SB203580-mediated inhibition of the p38 MAPK pathway	141
6.2.3	SP600125-mediated inhibition of the JNK pathway	147
6.3	Discussion	152
7	Characterisation of an <i>in vitro</i> model of neuroinflammation	161
7.1	Introduction	161
7.2	Results	164
7.2.1	Viability of neuronal cell lines	164
7.2.2	Profile of BV-2 cell activation in different culture medium	164
7.2.3	Co-culture of BV-2 cells with SK-N-SH cells	168
7.2.4	Trans-well cultures of BV-2 cells and SK-N-SH cells	168
7.2.5	Conditioned medium from BV-2 cells and SK-N-SH cell viability	170
7.3	Discussion	174
8	Inflammatory mediators involved in microglial-induced neuronal cell death	182
8.1	Introduction	182
8.2	Results	184
8.2.1	Cytotoxic effects of LPS and IFN- γ activated BV-2 cells on SK-N-SH cell viability	184
8.2.2	Cytoprotective effects of hypothermia in LPS and IFN- γ activated co-cultures.	184
8.2.3	<i>S</i> -Methylisothiourrea	188
8.2.4	NS-398	188
8.2.5	Propentofylline	191
8.2.6	Minocycline	191
8.3	Discussion	194
9	General Summary	203
	Appendix 1 Chemicals	210
	Appendix 2 Buffers and Solutions	211
	Appendix 3 Antibodies	213
	List of References	214

List of Figures

Figure 1.1 Schematic of the autotoxic loop hypothesis.....	2
Figure 1.2 Stages of microglial activation.....	12
Figure 3.1 Effect of LPS-induced activation on the morphology of BV-2 cells.	56
Figure 3.2 Constitutive PU.1 protein expression in BV-2 cells.	56
Figure 3.3 Effect of LPS-induced activation on the proliferation of BV-2 cells.....	58
Figure 3.4 Effect of LPS-induced activation on iNOS protein expression in BV-2 cells.....	58
Figure 3.5 Effect of LPS-induced activation on NO release in BV-2 cells.....	59
Figure 3.6 Effect of LPS-induced activation on BV-2 cell viability.	59
Figure 3.7 RT-PCR analysis of the time course of iNOS and COX-2 mRNA expression in LPS-stimulated BV-2 cells.....	61
Figure 3.8 Time course of iNOS and COX-2 protein expression in LPS-stimulated BV-2 cells.....	61
Figure 3.9 Time course of NO release in LPS-stimulated BV-2 cells.....	61
Figure 3.10 Effect of LPS-induced activation on release of pro-inflammatory cytokines (A) IL-6 and (B) TNF- α from BV-2 cells.....	62
Figure 3.11 Effect of LPS-induced activation on the phagocytic ability of BV-2 cells.	62
Figure 3.12 Effect of pre-treatment with IL-10 on LPS-induced iNOS protein expression in BV-2 cells.....	64
Figure 3.13 Effect of pre-treatment with IL-10 on LPS-induced COX-2 protein expression in BV-2 cells.	64
Figure 3.14 Effect of pre-treatment with IL-10 on LPS-induced IL-6 release from BV-2 cells.	65
Figure 3.15 Effect of pre-treatment with IL-10 on LPS-induced TNF- α release from BV-2 cells.	65
Figure 3.16 Effect of pre-treatment with 15d-PGJ ₂ on LPS-induced iNOS protein expression in BV-2 cells.....	66
Figure 3.17 Effect of pre-treatment with 15d-PGJ ₂ on LPS-induced COX-2 protein expression in BV-2 cells..	66
Figure 3.18 Effect of pre-treatment with 15d-PGJ ₂ on LPS-induced IL-6 release from BV-2 cells.	68
Figure 3.19 Effect of pre-treatment with 15d-PGJ ₂ on LPS-induced TNF- α release from BV-2 cells.	68
Figure 4.1 Effect of hypothermia on LPS-induced iNOS protein expression in BV-2 cells (ICC).....	78
Figure 4.2 Effect of hypothermia on LPS-induced iNOS protein expression in BV-2 cells (Cell counts).....	78
Figure 4.3 Effect of hypothermia on LPS-induced NO release in BV-2 cells.....	80
Figure 4.4 RT-PCR analysis of the effect of hypothermia on iNOS mRNA expression in LPS-stimulated BV-2 cells.....	80
Figure 4.5 Effect of hypothermia on LPS-induced iNOS protein expression in BV-2 cells (Western blot).	80
Figure 4.6 Effect of hypothermia on LPS-induced cytokine release in BV-2 cells.....	81
Figure 4.7 Effect of hypothermia on the nuclear translocation of NF- κ B in LPS-stimulated BV-2 cells.	81
Figure 4.8 Effect of hypothermia on the morphology of BV-2 cells.....	83
Figure 4.9 Effect of hypothermia on the proliferation of LPS-stimulated BV-2 cells.	83
Figure 4.10 Effect of hypothermia on LPS-stimulated COX-2 protein expression in BV-2 cells.....	84
Figure 4.11 Effect of hypothermia on LPS-induced PGE ₂ release in BV-2 cells.....	84

Figure 4.12 RT-PCR analysis of the effect of hypothermia on COX-2 mRNA expression in LPS-stimulated BV-2 cells.....	86
Figure 4.13 Effect of hypothermia on LPS-induced COX-2 protein expression in BV-2 cells.....	86
Figure 4.14 Effect of inhibition of iNOS with S-MT on COX-2 protein expression in LPS-stimulated BV-2 cells.....	86
Figure 5.1 LPS signalling pathways.....	95
Figure 5.2 LPS signalling through the MEK-ERK pathway.....	96
Figure 5.3 Time course of MEK-ERK pathway component protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.	97
Figure 5.4 Time course of MEK1/2 protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.	98
Figure 5.5 Time course of phospho-MEK1/2 protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	99
Figure 5.6 Time course of ERK1/2 protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	100
Figure 5.7 Time course of phospho-ERK1/2 protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	101
Figure 5.8 Time course of phospho-Elk-1 protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	102
Figure 5.9 LPS signalling through the JNK pathway.....	104
Figure 5.10 Time course of JNK pathway component protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.	105
Figure 5.11 Time course of JNK1 protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	106
Figure 5.12 Time course of JNK3 protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	107
Figure 5.13 Time course of phospho-JNK protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	108
Figure 5.14 Time course of c-Jun protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	109
Figure 5.15 Time course of phospho-c-Jun ^{Ser 63} protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	110
Figure 5.16 Time course of phospho-c-Jun ^{Ser 73} protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	111
Figure 5.17 LPS signalling through the p38 MAPK pathway.....	113
Figure 5.18 Time course of p38 MAPK protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	114
Figure 5.19 Time course of phospho-p38 MAPK protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.....	115

Figure 5.20 Time course of ATF-2 protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.	116
Figure 5.21 Time course of phospho-ATF-2 protein expression in LPS-stimulated BV-2 cells incubated under normothermic and hypothermic conditions.	117
Figure 5.22 LPS signalling through the NF- κ B MAPK pathway.	119
Figure 5.23 Time course of NF- κ B p65 protein expression in LPS-stimulated BV-2 cells incubated under normothermic or hypothermic conditions.	120
Figure 5.24 Time course protein expression in LPS-stimulated BV-2 cells incubated under normothermic or hypothermic conditions.	122
Figure 5.25 Time course of ATF-3 protein expression in LPS-stimulated BV-2 cells incubated under normothermic or hypothermic conditions.	123
Figure 5.26 Time course of PU.1 protein expression in LPS-stimulated BV-2 cells incubated under normothermic or hypothermic conditions.	124
Figure 5.27 Time course of cleaved caspase-3 protein expression in LPS-stimulated BV-2 cells incubated under normothermic or hypothermic conditions.	125
Figure 5.28 Time course of iNOS protein expression in LPS-stimulated BV-2 cells incubated under normothermic or hypothermic conditions.	126
Figure 5.29 Time course of COX-2 protein expression in LPS-stimulated BV-2 cells incubated under normothermic or hypothermic conditions.	127
Figure 6.1 Effect of pre-treatment with the MEK1/2 inhibitor, U0126, on BV-2 cell viability.	140
Figure 6.2 Effect of pre-treatment with the MEK1/2 inhibitor, U0126, on LPS-induced phosphorylation of MEK1/2.	140
Figure 6.3 Effect of pre-treatment with the MEK1/2 inhibitor, U0126, on LPS-induced phosphorylation of ERK1/2.	140
Figure 6.4 Effect of pre-treatment with the MEK1/2 inhibitor, U0126, on LPS-induced iNOS expression.	142
Figure 6.5 Effect of pre-treatment with the MEK1/2 inhibitor, U0126, on LPS-induced NO release.	142
Figure 6.6 Effect of pre-treatment with the MEK1/2 inhibitor, U0126, on LPS-induced COX-2 expression. ..	143
Figure 6.7 Effect of pre-treatment with the p38 MAPK inhibitor, SB203580, on BV-2 cell viability.	144
Figure 6.8 Effect of pre-treatment with the p38 MAPK inhibitor, SB203580, on LPS-induced phosphorylation of p38 MAPK.	144
Figure 6.9 Effect of pre-treatment with the p38 MAPK inhibitor, SB203580, on LPS-induced phosphorylation of ATF-2.	144
Figure 6.10 Effect of pre-treatment with the p38 MAPK inhibitor, SB203580, on LPS-induced iNOS protein expression.	145
Figure 6.11 Effect of pre-treatment with the p38 MAPK inhibitor, SB203580, on LPS-induced NO release. ...	145
Figure 6.12 Effect of pre-treatment with the p38 MAPK inhibitor, SB203580, on LPS-induced COX-2 expression.	146
Figure 6.13 Effect of pre-treatment with the JNK inhibitor, SP600125, on BV-2 cell viability (MTT).	146
Figure 6.14 Effect of pre-treatment with the JNK inhibitor, SP600125, on BV-2 cell viability.	148

Figure 6.15 Effect of pre-treatment with the JNK inhibitor, SP600125, on LPS-induced phosphorylation of JNK.	149
Figure 6.16 Effect of pre-treatment with the JNK inhibitor, SP600125, on LPS-induced phosphorylation of c-Jun.	149
Figure 6.17 Effect of pre-treatment with the JNK inhibitor, SP600125, on LPS-induced NO release.	149
Figure 6.18 Effect of pre-treatment with the JNK inhibitor, SP600125, on LPS-induced iNOS protein expression.	150
Figure 6.19 Effect of pre-treatment with the JNK inhibitor, SP600125, on LPS-induced COX-2 expression. .	151
Figure 7.1 In vitro model systems for investigating microglial-neuronal interactions.	163
Figure 7.2 Effect of LPS and IFN- γ on cell viability of (A) neuronally differentiated P19 cells, (B) SK-N-SH cells and (C) Neuro-2a cells.	165
Figure 7.3 Effect of LPS and IFN- γ on cell viability of BV-2 cells in (A) DMEM, (B) RPMI and (C) MEM.	166
Figure 7.4 Effect of LPS and IFN- γ on NO release in BV-2 cells cultured in different media.	167
Figure 7.5 Effect of LPS and IFN- γ on cell number in co-cultures of BV-2 cells and SK-N-SH cells.	167
Figure 7.6 Effect of LPS and IFN- γ on cell viability in co-cultures of BV-2 cells and SK-N-SH cells.	169
Figure 7.7 Effect of LPS and IFN- γ on NO release in co-cultures of BV-2 cells and SK-N-SH cells.	169
Figure 7.8 Effect of LPS and IFN- γ on cell number in trans-well cultures of BV-2 cells and SK-N-SH cells. .	171
Figure 7.9 Effect of LPS and IFN- γ on cell viability in trans-well cultures of BV-2 cells and SK-N-SH cells.	172
Figure 7.10 Effect of LPS and IFN- γ on NO release in trans-well cultures of BV-2 cells and SK-N-SH cells.	172
Figure 7.11 Effect of LPS and IFN- γ on cell viability in conditioned medium cultures of BV-2 cells and SK-N-SH cells.	173
Figure 7.12 Effect of LPS and IFN- γ on NO release in conditioned medium cultures of BV-2 cells and SK-N-SH cells.	173
Figure 8.1 Effect of LPS/IFN- γ on cell number in co-cultures of BV-2 cells and SK-N-SH cells.	185
Figure 8.2 Effect of LPS/IFN- γ on cell viability in co-cultures of BV-2 and SK-N-SH cells.	186
Figure 8.3 Effect of hypothermia on cell number of LPS/IFN- γ -stimulated co-culture of BV-2 and SK-N-SH cells.	186
Figure 8.4 Effect of hypothermia on cell viability of LPS/IFN- γ -stimulated co-culture of BV-2 and SK-N-SH cells.	187
Figure 8.5 Effect of hypothermia on NO release in LPS or LPS/IFN- γ -stimulated co-culture of BV-2 and SK-N-SH cells.	187
Figure 8.6 Effect of the iNOS inhibitor S-MT on (A) cell viability and (B) NO release in mono- and co-culture of BV-2 cells and SK-N-SH cells.	189
Figure 8.7 Effect of the COX-2 inhibitor NS-398 on (A) cell viability and (B) PGE ₂ release in mono- and co-culture of BV-2 cells and SK-N-SH cells.	190
Figure 8.8 Effect of the broad spectrum microglial inhibitor propentofylline on (A) cell viability and (B) TNF α release in mono- and co-culture of BV-2 cells and SK-N-SH cells.	192
Figure 8.9 Effect of the broad spectrum microglial inhibitor minocycline on (A) cell viability and (B) NO release in mono- and co-culture of BV-2 cells and SK-N-SH cells.	193

List of Tables

Table 2.1 Concentrations and conditions of cell culture stimulants	43
Table 2.2 Concentrations and incubation times for inhibitors.....	43
Table 2.3 PCR primers	47
Table 2.4 RT-PCR conditions	47
Table 6.1 MAPK inhibitor and stimulus concentrations and incubation times	139

Abbreviations

A β	β -amyloid
AD	Alzheimer's disease
ALS	Amyotrophic lateral sclerosis
AP-1	Activator protein-1
APOE	Apolipoprotein E
APP	Amyloid precursor protein
ATF	Activating transcription factor
BBB	Blood-brain barrier
BrdU	5-bromo-2'-deoxyuridine
CD	Cluster of differentiation
C/EBP	CCAAT-enhancer binding proteins
CNS	Central nervous system
CO ₂	Carbon dioxide
COX	Cyclooxygenase
CRE	CREB response element
CREB	cAMP response element binding protein
CSF	Cerebrospinal fluid
DMSO	Dimethylsulphoxide
DNA	Deoxyribonucleic acid
eNOS	Endothelial nitric oxide synthase
EP	Prostaglandin E ₂ receptor
ERK1/2	Extracellular signal-regulated kinase
FAD	Flavin adenine dinucleotide
FMN	Flavin mononucleotide
GAPDH	Glyceraldehyde-3-phosphate dehydrogenase
GFAP	Glial fibrillary acidic protein
H ₂ O ₂	Hydrogen peroxide
HD	Huntington's disease
HLA	Human leukocyte antigen
6-OHDA	6-hydroxydopamine
4-HNE	4-hydroxynonenal
HOCl	Hypochlorous acid
ICAM-1	Intracellular adhesion molecule
ICC	Immunocytochemistry
IFN	Interferon
IFNR	IFN- γ receptor
IKK	I κ B kinase
IL	Interleukin
IL-6R	Interleukin-6 receptor

iNOS	inducible nitric oxide synthase
IRAK	IL-1-receptor-associated kinase
IRF	Interferon regulatory factor
JIP	JNK-interacting protein
JNK	c-Jun N-terminal kinase
LPB	LPS-binding protein
LPS	Lipopolysaccharide
MAC	Membrane attack complex
MAPK	Mitogen-activated protein kinase
MCAO	middle cerebral artery occlusion
MEK1/2	MAPK/ERK kinase
MHC	Major histocompatibility complex
MPO	Myeloperoxidase
MPP ⁺	1-methyl-4-phenylpyridinium
MPTP	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MRI	Magnetic resonance imaging
MS	Multiple sclerosis
NADPH	Nicotinamide adenine dinucleotide phosphate
NF- κ B	Nuclear factor- κ B
NFT	Neurofibrillary tangle
NMDA	N-methyl-D-aspartate
nNOS	Neuronal nitric oxide synthase
NO	Nitric oxide
NO ₂	Nitrogen dioxide
NOS	Nitric oxide synthase
NSAID	Non-steroidal anti-inflammatory drug
O ₂ ⁻	Superoxide
OH ⁻	Hydroxyl radical
ONOO ⁻	Peroxynitrite
PAMP	Pathogen-associated molecular patterns
PCNA	Proliferating cell nuclear antigen
PD	Parkinson's disease
PDZ	Post-synaptic density-95/discs large/zonula occludens-1
PET	polyethylene terephthalate
PG	Prostaglandin
15d-PGJ ₂	15-deoxy- $\Delta^{12,14}$ -PGJ ₂
PHF	Paired helical filament
PKC	Protein kinase C
PMA	Phorbol 12-myristate 13-acetate
PPAR	Peroxisome proliferator-activated receptor
RNS	Reactive nitrogen species
ROS	Reactive oxygen species

RT-PCR	Reverse transcription-polymerase chain reaction
sIL-6R	Soluble interleukin-6 receptor
S-MT	<i>S</i> -methylisothiourea
SNpc	Substantia nigra pars compacta
SRE	Serum response element
STAT	Signal transducers and activators of transcription
TCF	Ternary complex factor
TGF	Transforming growth factor
TIR	Toll/interleukin-1 receptor
TLR	Toll-like receptor
TNF	Tumour necrosis factor
TNFR1	p55 TNF receptor
TNFR2	p75 TNF receptor
TRAF6	TNF-receptor-associated factor